Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Non-Current Liabilities (2016 - 2022)

Historic Other Non-Current Liabilities for Spero Therapeutics (SPRO) over the last 7 years, with Q3 2022 value amounting to $100000.0.

  • Spero Therapeutics' Other Non-Current Liabilities changed N/A to $100000.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $100000.0, marking a year-over-year change of. This contributed to the annual value of $802000.0 for FY2021, which is N/A changed from last year.
  • Spero Therapeutics' Other Non-Current Liabilities amounted to $100000.0 in Q3 2022.
  • Spero Therapeutics' Other Non-Current Liabilities' 5-year high stood at $1.0 million during Q1 2022, with a 5-year trough of $100000.0 in Q2 2022.
  • In the last 5 years, Spero Therapeutics' Other Non-Current Liabilities had a median value of $223000.0 in 2018 and averaged $313583.3.
  • Per our database at Business Quant, Spero Therapeutics' Other Non-Current Liabilities surged by 276.5% in 2018 and then crashed by 1031.39% in 2020.
  • Spero Therapeutics' Other Non-Current Liabilities (Quarter) stood at $223000.0 in 2018, then changed by 0.0% to $223000.0 in 2019, then fell by 10.31% to $200000.0 in 2020, then soared by 301.0% to $802000.0 in 2021, then crashed by 87.53% to $100000.0 in 2022.
  • Its Other Non-Current Liabilities stands at $100000.0 for Q3 2022, versus $100000.0 for Q2 2022 and $1.0 million for Q1 2022.